Inagaki K, et al. - Researchers performed a retrospective analysis using the 2014 Nationwide Readmissions Database, capturing 49.3% of US hospitalizations, to assess the outcomes of methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission. Outcomes suggest a common occurrence of 30-day readmission after S. aureus bacteremia. Readmission costs $12425 (standard error, SE: 174) /case overall, and $19186 (SE: 623) for those with bacteremia recurrence. They observed readmission for bacteremia recurrence, increased mortality, and longer hospitalization in correlation with MRSA bacteremia. These findings emphasize continuous efforts to optimize patient care, especially for those with risk factors, to reduce readmission and associated morbidity and mortality in patients with S. aureus bacteremia.